Your Article Summary
See Latest ArticlesProactive management of adverse events maintains the clinical benefit of ixabepilone
The Oncologist, 06/01/09
Yardley DA - Ixabepilone is an effective agent for treating advanced breast cancer, even in pts who experience disease progression following anthracycline, taxane, and capecitabine therapy. Although this agent is generally well tolerated, by effectively managing adverse events, clinicians can ensure that pts derive the maximum benefit whether given as a single agent or in combination with capecitabine.
Methods- Article reviews the safety profile of single-agent ixabepilone and combination of ixabepilone plus capecitabine therapy
- Steps to effectively manage and prevent common adverse events are also outlined
- Ixabepilone is generally well tolerated; its toxicity profile does not overlap with that of capecitabine
- Common toxicities: peripheral sensory neuropathy and neutropenia
- AEs can be effectively managed by:
- monitoring patients and then
- depending on severity, instituting a treatment delay until recovery and
- reducing the ixabepilone dose for subsequent treatment cycles
- Ixabepilone dose reductions are recommended for most grade 3 events
- Treatment discontinuation is recommended for persistent grade 3 neuropathy or grade 4 nonhematological toxicity
- Because ixabepilone exposure is greater in pts with hepatic impairment, dose adjustments and restrictions are recommended according to the degree of hepatic impairment
- Pts should be premedicated with oral H1 and H2 antihistamines to prevent hypersensitivity reactions
Related Articles
Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: A Gynecologic Oncology Group Study
Journal of Clinical Oncology, 11/24/09
Relevance Score: 87%
Anthracycline- and/or taxane-resistant breast cancer: Results of a literature review to determine the clinical challenges and current treatment trends
Clinical Therapeutics, 10/15/09
Relevance Score: 80%
Today in Breast...keeping you current
Receive free subspecialty "5-minute updates" via email
Extracellular Signal–Regulated Kinase Signaling Pathway Regulates Breast Cancer Cell Migration by Maintaining slug Expression
Cancer Research, 12/20/09
Flat epithelial atypia is a common subtype of B3 breast lesions and associated with noninvasive cancer but not with invasive cancer in final excision histology
Human Pathology, 12/19/09
Screening for Founder Mutations in BRCA1 and BRCA2 in Unselected Jewish Women
Journal of Clinical Oncology, 12/18/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia
Haematologica, 12/18/09
Safety and Efficacy of Romiplostim in Patients With Lower-Risk Myelodysplastic Syndrome and Thrombocytopenia
Journal of Clinical Oncology, 12/18/09
Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance
Journal of Clinical Oncology, 12/18/09
Today in Side Effects...keeping you current
Receive free subspecialty "5-minute updates" via email
Risk analysis of severe myelotoxicity with temozolomide: The effects of clinical and genetic factors
Neuro-Oncology, 12/17/09
Oxaliplatin-induced Lhermitte's phenomenon as a manifestation of severe generalized neurotoxicity
Oncology (Karger), 12/16/09
Cardiotoxicity of Anticancer Drugs: The Need for Cardio-Oncology and Cardio-Oncological Prevention
Journal of the National Cancer Institute, 12/15/09